Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial

Hiroki Teragawa,1 Takeshi Morimoto,2 Yuichi Fujii,1 Tomohiro Ueda,1 Mio Sakuma,2 Michio Shimabukuro,3 Osamu Arasaki,4 Koichi Node,5 Takashi Nomiyama,6 Shinichiro Ueda7 1Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan; 2Department of Clinical Epidemiology, Hyogo College...

Full description

Bibliographic Details
Main Authors:	Teragawa H, Morimoto T, Fujii Y, Ueda T, Sakuma M, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Ueda S
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-12-01
Series:	Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Subjects:	c-reactive protein dipeptidylpeptidase-4 dpp-4 inhibitor inflammation interleukin-6 white blood cell
Online Access:	https://www.dovepress.com/effect-of-anagliptin-versus-sitagliptin-on-inflammatory-markers-sub-an-peer-reviewed-article-DMSO

Similar Items

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial
by: Hiroyuki Hirai, et al.
Published: (2019-12-01)

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
by: Atsuko Chihara, et al.
Published: (2019-11-01)

Sitagliptin Modulates Oxidative, Nitrative and Halogenative Stress and Inflammatory Response in Rat Model of Hepatic Ischemia-Reperfusion
by: Małgorzata Trocha, et al.
Published: (2021-07-01)

New combination treatments in the management of diabetes: focus on sitagliptin – metformin
by: Jennifer Green, et al.
Published: (2008-08-01)

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
by: Masato Furuhashi, et al.
Published: (2020-06-01)

Actions and antidiabetic potential of amino terminally modified analogues of glucose dependent insulinotropic polypeptide
by: Gault, Victor Alan
Published: (2001)

Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01)

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
by: Hyun Min Kim, et al.
Published: (2015-03-01)

Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
by: Elena Nikolaevna Trunina, et al.
Published: (2011-06-01)

Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors
by: Chin-Ying Ray, et al.
Published: (2021-04-01)

Melatonin postconditioning combined with sitagliptin exerts full cardioprotection in diabetic hearts of aged rats through an AMPK-dependent mechanism
by: Song Ronggang, et al.
Published: (2021-01-01)

Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats
by: Al-Rasheed NM, et al.
Published: (2016-06-01)

DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model
by: Amy L. Wilson, et al.
Published: (2021-01-01)

Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE)
by: Naoto Katakami, et al.
Published: (2018-02-01)

Sitagliptin: a potential drug for the treatment of COVID-19?
by: Bardaweel Sanaa K., et al.
Published: (2021-06-01)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

The emerging role of incretins in the pathophysiology of insulin resistance in type 1 diabetes.
by: Gorana Mirošević, et al.
Published: (2017-09-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)

ADVANTAGES, SAFETY AND PROSPECTS OF SITAGLIPTIN APPLICATION IN TYPE 2 DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE
by: I. A. Bonda
Published: (2017-07-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01)

DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs
by: Jianqiang Zhang, et al.
Published: (2019-05-01)

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study
by: Hiroshi Sakura, et al.
Published: (2016-12-01)

Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study
by: Lui Ng, et al.
Published: (2021-07-01)

Anti-Diabetic Activity of Whey Proteins
by: Agarkova Eugeniya Yu., et al.
Published: (2020-06-01)

Linagliptin use in older individuals with type 2 diabetes
by: Pratley RE
Published: (2014-07-01)

Peptide Vaccines for Hypertension and Diabetes Mellitus
by: Hironori Nakagami, et al.
Published: (2014-11-01)

Dual-function peptides derived from egg white ovalbumin: Bioinformatics identification with validation using in vitro assay
by: Mohd Adam Salim Mohd Salim, et al.
Published: (2020-01-01)

Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China
by: Wen-Qiang Lin, et al.
Published: (2021-08-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma
by: Jiali Carrie Huang, et al.
Published: (2021-04-01)

CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN
by: N. A. Petunina, et al.
Published: (2017-12-01)

Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring
by: Arumugam Kodimuthali, et al.
Published: (2010-07-01)

Screening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4
by: Zhaokai Wang, et al.
Published: (2017-05-01)

DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo
by: Masahiko Ishida, et al.
Published: (2019-01-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus
by: Masato Furuhashi, et al.
Published: (2020-09-01)

Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride
by: Woodman OL, et al.
Published: (2019-08-01)

Editorial – COVID-19 pandemic: is it time to learn about DPP-4/CD26?
by: M. Maia Pinheiro, et al.
Published: (2020-04-01)